Krystal Biotech Inc.

AI Score

0

Unlock

142.06
-8.25 (-5.49%)
At close: Jan 14, 2025, 3:59 PM
142.64
0.41%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 114.2
Market Cap 4.09B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 1.77
PE Ratio (ttm) 80.26
Forward PE n/a
Analyst Buy
Ask 180.53
Volume 345,818
Avg. Volume (20D) 256,090
Open 152.94
Previous Close 150.31
Day's Range 141.72 - 152.94
52-Week Range 107.50 - 219.34
Beta undefined

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 229
Stock Exchange NASDAQ
Ticker Symbol KRYS

Analyst Forecast

According to 7 analyst ratings, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is $212, which is an increase of 49.23% from the latest price.

Buy 85.71%
Hold 14.29%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Krystal Biotech Inc. is scheduled to release its earnings on Feb 24, 2025, before market opens.
Analysts project revenue of $95.89M, reflecting a 127.53% YoY growth and earnings per share of 0.96, making a 220.00% increase YoY.
4 months ago · Source
+7.45%
Krystal Biotech shares are trading higher after St... Unlock content with Pro Subscription
8 months ago · Source
-2.58%
Krystal Biotech shares are trading lower after the company reported Q1 financial results.